Nasal and sinus cavity tumors are rare but are of special concern due to their close location to the eyes and brain. The most common tumors are squamous cell carcinoma and adenocarcinoma.
Sinus cancers are categorized into Stages 0, I, II, III, and IV. The stage is considered more advanced as a tumor grows and involves more areas of the sinuses.
For more detailed, technical information about nasal and sinus cavity cancer, please read our sinus and nasal cavity cancer patient information sheet.
The physicians at UT Southwestern Medical Center are experts at diagnosing and treating the condition.
Early symptoms are often nonspecific and may be confused with allergies or a sinus infection. As tumors grow, they may cause nasal blockage or bleeding. Larger tumors can cause severe headaches or blurry vision.
Other symptoms include:
Doctors have a number of ways to diagnose these cancers.
At UT Southwestern, our physicians participate in a multidisciplinary skull base tumor board that works closely together to optimize the care of these difficult tumors. Some of the treatment options we offer include:
This treatment option is used in select cases of aggressive sinus cancers before or after surgery. It may also be used to treat recurrent cancer.
This treatment uses high-dose X-rays or other high-energy rays to kill cancer cells. Radiation is typically used after surgery to minimize the risk of cancer recurrence.
Nasal and sinus cavity tumors traditionally had to be removed through an incision on the face and the removal of the forehead bone flap, a procedure known as a craniotomy. The development of minimally invasive endoscopic resection now makes it possible to remove the tumor directly through the nose. Endoscopic surgery decreases complications and leads to quicker recovery times.
Tumors with extensive brain involvement may still require a craniotomy.
Your recovery depends on the location and type of the cancer, the stage of the cancer, and your general state of health. The five-year survival rates range from 80 to 90 percent for small cancers that have not spread to 10 to 20 percent for advanced cancers.